Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-Current Assets: 2016-2024

Historic Non-Current Assets for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $11.3 million.

  • Tg Therapeutics' Non-Current Assets rose 3460.14% to $425.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $425.3 million, marking a year-over-year increase of 3460.14%. This contributed to the annual value of $11.3 million for FY2024, which is 2.69% down from last year.
  • As of FY2024, Tg Therapeutics' Non-Current Assets stood at $11.3 million, which was down 2.69% from $11.6 million recorded in FY2023.
  • Tg Therapeutics' Non-Current Assets' 5-year high stood at $48.7 million during FY2021, with a 5-year trough of $11.3 million in FY2024.
  • Its 3-year average for Non-Current Assets is $16.1 million, with a median of $11.6 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 250.05% in 2021, then crashed by 53.97% in 2023.
  • Tg Therapeutics' Non-Current Assets (Yearly) stood at $13.9 million in 2020, then spiked by 250.05% to $48.7 million in 2021, then slumped by 48.01% to $25.3 million in 2022, then plummeted by 53.97% to $11.6 million in 2023, then decreased by 2.69% to $11.3 million in 2024.